Global Cancer Generics Market Research Report 2023

The global Cancer Generics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Cancer Generics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Cancer Generics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Cancer Generics in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Cancer Generics include Teva Pharmaceuticals, Pfizer, Accord Healthcare, Amneal Pharmaceuticals, Mylan, DrReddy Laboratories, Bedford Pharma, Hikma and Cipla, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Cancer Generics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Generics.

The Cancer Generics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cancer Generics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cancer Generics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cancer Generics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Chemotherapy

1.2.3 Biological Targeted Therapy Drugs

1.2.4 Prescription Drugs

1.2.5 Chinese Patent Medicine

1.2.6 Other

1.3 Market by Application

1.3.1 Global Cancer Generics Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Drug Center

1.3.5 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Cancer Generics Market Perspective (2018-2029)

2.2 Cancer Generics Growth Trends by Region

2.2.1 Global Cancer Generics Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Cancer Generics Historic Market Size by Region (2018-2023)

2.2.3 Cancer Generics Forecasted Market Size by Region (2024-2029)

2.3 Cancer Generics Market Dynamics

2.3.1 Cancer Generics Industry Trends

2.3.2 Cancer Generics Market Drivers

2.3.3 Cancer Generics Market Challenges

2.3.4 Cancer Generics Market Restraints

3.1 Global Top Cancer Generics Players by Revenue

3.1.1 Global Top Cancer Generics Players by Revenue (2018-2023)

3.1.2 Global Cancer Generics Revenue Market Share by Players (2018-2023)

3.2 Global Cancer Generics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Cancer Generics Revenue

3.4 Global Cancer Generics Market Concentration Ratio

3.4.1 Global Cancer Generics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cancer Generics Revenue in 2022

3.5 Cancer Generics Key Players Head office and Area Served

3.6 Key Players Cancer Generics Product Solution and Service

3.7 Date of Enter into Cancer Generics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Cancer Generics Historic Market Size by Type (2018-2023)

4.2 Global Cancer Generics Forecasted Market Size by Type (2024-2029)

5.1 Global Cancer Generics Historic Market Size by Application (2018-2023)

5.2 Global Cancer Generics Forecasted Market Size by Application (2024-2029)

6.1 North America Cancer Generics Market Size (2018-2029)

6.2 North America Cancer Generics Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Cancer Generics Market Size by Country (2018-2023)

6.4 North America Cancer Generics Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Cancer Generics Market Size (2018-2029)

7.2 Europe Cancer Generics Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Cancer Generics Market Size by Country (2018-2023)

7.4 Europe Cancer Generics Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Cancer Generics Market Size (2018-2029)

8.2 Asia-Pacific Cancer Generics Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Cancer Generics Market Size by Region (2018-2023)

8.4 Asia-Pacific Cancer Generics Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Cancer Generics Market Size (2018-2029)

9.2 Latin America Cancer Generics Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Cancer Generics Market Size by Country (2018-2023)

9.4 Latin America Cancer Generics Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Cancer Generics Market Size (2018-2029)

10.2 Middle East & Africa Cancer Generics Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Cancer Generics Market Size by Country (2018-2023)

10.4 Middle East & Africa Cancer Generics Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Teva Pharmaceuticals

11.1.1 Teva Pharmaceuticals Company Detail

11.1.2 Teva Pharmaceuticals Business Overview

11.1.3 Teva Pharmaceuticals Cancer Generics Introduction

11.1.4 Teva Pharmaceuticals Revenue in Cancer Generics Business (2018-2023)

11.1.5 Teva Pharmaceuticals Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Cancer Generics Introduction

11.2.4 Pfizer Revenue in Cancer Generics Business (2018-2023)

11.2.5 Pfizer Recent Development

11.3 Accord Healthcare

11.3.1 Accord Healthcare Company Detail

11.3.2 Accord Healthcare Business Overview

11.3.3 Accord Healthcare Cancer Generics Introduction

11.3.4 Accord Healthcare Revenue in Cancer Generics Business (2018-2023)

11.3.5 Accord Healthcare Recent Development

11.4 Amneal Pharmaceuticals

11.4.1 Amneal Pharmaceuticals Company Detail

11.4.2 Amneal Pharmaceuticals Business Overview

11.4.3 Amneal Pharmaceuticals Cancer Generics Introduction

11.4.4 Amneal Pharmaceuticals Revenue in Cancer Generics Business (2018-2023)

11.4.5 Amneal Pharmaceuticals Recent Development

11.5 Mylan

11.5.1 Mylan Company Detail

11.5.2 Mylan Business Overview

11.5.3 Mylan Cancer Generics Introduction

11.5.4 Mylan Revenue in Cancer Generics Business (2018-2023)

11.5.5 Mylan Recent Development

11.6 DrReddy Laboratories

11.6.1 DrReddy Laboratories Company Detail

11.6.2 DrReddy Laboratories Business Overview

11.6.3 DrReddy Laboratories Cancer Generics Introduction

11.6.4 DrReddy Laboratories Revenue in Cancer Generics Business (2018-2023)

11.6.5 DrReddy Laboratories Recent Development

11.7 Bedford Pharma

11.7.1 Bedford Pharma Company Detail

11.7.2 Bedford Pharma Business Overview

11.7.3 Bedford Pharma Cancer Generics Introduction

11.7.4 Bedford Pharma Revenue in Cancer Generics Business (2018-2023)

11.7.5 Bedford Pharma Recent Development

11.8 Hikma

11.8.1 Hikma Company Detail

11.8.2 Hikma Business Overview

11.8.3 Hikma Cancer Generics Introduction

11.8.4 Hikma Revenue in Cancer Generics Business (2018-2023)

11.8.5 Hikma Recent Development

11.9 Cipla

11.9.1 Cipla Company Detail

11.9.2 Cipla Business Overview

11.9.3 Cipla Cancer Generics Introduction

11.9.4 Cipla Revenue in Cancer Generics Business (2018-2023)

11.9.5 Cipla Recent Development

11.10 Shilpa Medicare

11.10.1 Shilpa Medicare Company Detail

11.10.2 Shilpa Medicare Business Overview

11.10.3 Shilpa Medicare Cancer Generics Introduction

11.10.4 Shilpa Medicare Revenue in Cancer Generics Business (2018-2023)

11.10.5 Shilpa Medicare Recent Development

11.11 Fresenius Kabi

11.11.1 Fresenius Kabi Company Detail

11.11.2 Fresenius Kabi Business Overview

11.11.3 Fresenius Kabi Cancer Generics Introduction

11.11.4 Fresenius Kabi Revenue in Cancer Generics Business (2018-2023)

11.11.5 Fresenius Kabi Recent Development

11.12 Zydus Pharmaceuticals

11.12.1 Zydus Pharmaceuticals Company Detail

11.12.2 Zydus Pharmaceuticals Business Overview

11.12.3 Zydus Pharmaceuticals Cancer Generics Introduction

11.12.4 Zydus Pharmaceuticals Revenue in Cancer Generics Business (2018-2023)

11.12.5 Zydus Pharmaceuticals Recent Development

11.13 Neopharm

11.13.1 Neopharm Company Detail

11.13.2 Neopharm Business Overview

11.13.3 Neopharm Cancer Generics Introduction

11.13.4 Neopharm Revenue in Cancer Generics Business (2018-2023)

11.13.5 Neopharm Recent Development

11.14 Netco

11.14.1 Netco Company Detail

11.14.2 Netco Business Overview

11.14.3 Netco Cancer Generics Introduction

11.14.4 Netco Revenue in Cancer Generics Business (2018-2023)

11.14.5 Netco Recent Development

11.15 Mayne Pharma

11.15.1 Mayne Pharma Company Detail

11.15.2 Mayne Pharma Business Overview

11.15.3 Mayne Pharma Cancer Generics Introduction

11.15.4 Mayne Pharma Revenue in Cancer Generics Business (2018-2023)

11.15.5 Mayne Pharma Recent Development

11.16 Alvogen

11.16.1 Alvogen Company Detail

11.16.2 Alvogen Business Overview

11.16.3 Alvogen Cancer Generics Introduction

11.16.4 Alvogen Revenue in Cancer Generics Business (2018-2023)

11.16.5 Alvogen Recent Development

11.17 Glenmark

11.17.1 Glenmark Company Detail

11.17.2 Glenmark Business Overview

11.17.3 Glenmark Cancer Generics Introduction

11.17.4 Glenmark Revenue in Cancer Generics Business (2018-2023)

11.17.5 Glenmark Recent Development

11.18 HBT Labs

11.18.1 HBT Labs Company Detail

11.18.2 HBT Labs Business Overview

11.18.3 HBT Labs Cancer Generics Introduction

11.18.4 HBT Labs Revenue in Cancer Generics Business (2018-2023)

11.18.5 HBT Labs Recent Development

11.19 Gland

11.19.1 Gland Company Detail

11.19.2 Gland Business Overview

11.19.3 Gland Cancer Generics Introduction

11.19.4 Gland Revenue in Cancer Generics Business (2018-2023)

11.19.5 Gland Recent Development

11.20 Qilu Pharmaceuticals

11.20.1 Qilu Pharmaceuticals Company Detail

11.20.2 Qilu Pharmaceuticals Business Overview

11.20.3 Qilu Pharmaceuticals Cancer Generics Introduction

11.20.4 Qilu Pharmaceuticals Revenue in Cancer Generics Business (2018-2023)

11.20.5 Qilu Pharmaceuticals Recent Development

11.21 Akorn Pharmaceuticals

11.21.1 Akorn Pharmaceuticals Company Detail

11.21.2 Akorn Pharmaceuticals Business Overview

11.21.3 Akorn Pharmaceuticals Cancer Generics Introduction

11.21.4 Akorn Pharmaceuticals Revenue in Cancer Generics Business (2018-2023)

11.21.5 Akorn Pharmaceuticals Recent Development

11.22 MSN Group

11.22.1 MSN Group Company Detail

11.22.2 MSN Group Business Overview

11.22.3 MSN Group Cancer Generics Introduction

11.22.4 MSN Group Revenue in Cancer Generics Business (2018-2023)

11.22.5 MSN Group Recent Development

11.23 Wockhardt

11.23.1 Wockhardt Company Detail

11.23.2 Wockhardt Business Overview

11.23.3 Wockhardt Cancer Generics Introduction

11.23.4 Wockhardt Revenue in Cancer Generics Business (2018-2023)

11.23.5 Wockhardt Recent Development

11.24 Rising Pharma

11.24.1 Rising Pharma Company Detail

11.24.2 Rising Pharma Business Overview

11.24.3 Rising Pharma Cancer Generics Introduction

11.24.4 Rising Pharma Revenue in Cancer Generics Business (2018-2023)

11.24.5 Rising Pharma Recent Development

11.25 Apotex

11.25.1 Apotex Company Detail

11.25.2 Apotex Business Overview

11.25.3 Apotex Cancer Generics Introduction

11.25.4 Apotex Revenue in Cancer Generics Business (2018-2023)

11.25.5 Apotex Recent Development

11.26 Taro Pharmaceuticals

11.26.1 Taro Pharmaceuticals Company Detail

11.26.2 Taro Pharmaceuticals Business Overview

11.26.3 Taro Pharmaceuticals Cancer Generics Introduction

11.26.4 Taro Pharmaceuticals Revenue in Cancer Generics Business (2018-2023)

11.26.5 Taro Pharmaceuticals Recent Development

11.27 Sun Pharma

11.27.1 Sun Pharma Company Detail

11.27.2 Sun Pharma Business Overview

11.27.3 Sun Pharma Cancer Generics Introduction

11.27.4 Sun Pharma Revenue in Cancer Generics Business (2018-2023)

11.27.5 Sun Pharma Recent Development

11.28 Alkem Laboratories

11.28.1 Alkem Laboratories Company Detail

11.28.2 Alkem Laboratories Business Overview

11.28.3 Alkem Laboratories Cancer Generics Introduction

11.28.4 Alkem Laboratories Revenue in Cancer Generics Business (2018-2023)

11.28.5 Alkem Laboratories Recent Development

11.29 Endo Pharma

11.29.1 Endo Pharma Company Detail

11.29.2 Endo Pharma Business Overview

11.29.3 Endo Pharma Cancer Generics Introduction

11.29.4 Endo Pharma Revenue in Cancer Generics Business (2018-2023)

11.29.5 Endo Pharma Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Cancer Generics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Chemotherapy

    Table 3. Key Players of Biological Targeted Therapy Drugs

    Table 4. Key Players of Prescription Drugs

    Table 5. Key Players of Chinese Patent Medicine

    Table 6. Key Players of Other

    Table 7. Global Cancer Generics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Cancer Generics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Cancer Generics Market Size by Region (2018-2023) & (US$ Million)

    Table 10. Global Cancer Generics Market Share by Region (2018-2023)

    Table 11. Global Cancer Generics Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 12. Global Cancer Generics Market Share by Region (2024-2029)

    Table 13. Cancer Generics Market Trends

    Table 14. Cancer Generics Market Drivers

    Table 15. Cancer Generics Market Challenges

    Table 16. Cancer Generics Market Restraints

    Table 17. Global Cancer Generics Revenue by Players (2018-2023) & (US$ Million)

    Table 18. Global Cancer Generics Market Share by Players (2018-2023)

    Table 19. Global Top Cancer Generics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Generics as of 2022)

    Table 20. Ranking of Global Top Cancer Generics Companies by Revenue (US$ Million) in 2022

    Table 21. Global 5 Largest Players Market Share by Cancer Generics Revenue (CR5 and HHI) & (2018-2023)

    Table 22. Key Players Headquarters and Area Served

    Table 23. Key Players Cancer Generics Product Solution and Service

    Table 24. Date of Enter into Cancer Generics Market

    Table 25. Mergers & Acquisitions, Expansion Plans

    Table 26. Global Cancer Generics Market Size by Type (2018-2023) & (US$ Million)

    Table 27. Global Cancer Generics Revenue Market Share by Type (2018-2023)

    Table 28. Global Cancer Generics Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 29. Global Cancer Generics Revenue Market Share by Type (2024-2029)

    Table 30. Global Cancer Generics Market Size by Application (2018-2023) & (US$ Million)

    Table 31. Global Cancer Generics Revenue Market Share by Application (2018-2023)

    Table 32. Global Cancer Generics Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 33. Global Cancer Generics Revenue Market Share by Application (2024-2029)

    Table 34. North America Cancer Generics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. North America Cancer Generics Market Size by Country (2018-2023) & (US$ Million)

    Table 36. North America Cancer Generics Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Europe Cancer Generics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Europe Cancer Generics Market Size by Country (2018-2023) & (US$ Million)

    Table 39. Europe Cancer Generics Market Size by Country (2024-2029) & (US$ Million)

    Table 40. Asia-Pacific Cancer Generics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Asia-Pacific Cancer Generics Market Size by Region (2018-2023) & (US$ Million)

    Table 42. Asia-Pacific Cancer Generics Market Size by Region (2024-2029) & (US$ Million)

    Table 43. Latin America Cancer Generics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Latin America Cancer Generics Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Latin America Cancer Generics Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Middle East & Africa Cancer Generics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 47. Middle East & Africa Cancer Generics Market Size by Country (2018-2023) & (US$ Million)

    Table 48. Middle East & Africa Cancer Generics Market Size by Country (2024-2029) & (US$ Million)

    Table 49. Teva Pharmaceuticals Company Detail

    Table 50. Teva Pharmaceuticals Business Overview

    Table 51. Teva Pharmaceuticals Cancer Generics Product

    Table 52. Teva Pharmaceuticals Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 53. Teva Pharmaceuticals Recent Development

    Table 54. Pfizer Company Detail

    Table 55. Pfizer Business Overview

    Table 56. Pfizer Cancer Generics Product

    Table 57. Pfizer Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 58. Pfizer Recent Development

    Table 59. Accord Healthcare Company Detail

    Table 60. Accord Healthcare Business Overview

    Table 61. Accord Healthcare Cancer Generics Product

    Table 62. Accord Healthcare Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 63. Accord Healthcare Recent Development

    Table 64. Amneal Pharmaceuticals Company Detail

    Table 65. Amneal Pharmaceuticals Business Overview

    Table 66. Amneal Pharmaceuticals Cancer Generics Product

    Table 67. Amneal Pharmaceuticals Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 68. Amneal Pharmaceuticals Recent Development

    Table 69. Mylan Company Detail

    Table 70. Mylan Business Overview

    Table 71. Mylan Cancer Generics Product

    Table 72. Mylan Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 73. Mylan Recent Development

    Table 74. DrReddy Laboratories Company Detail

    Table 75. DrReddy Laboratories Business Overview

    Table 76. DrReddy Laboratories Cancer Generics Product

    Table 77. DrReddy Laboratories Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 78. DrReddy Laboratories Recent Development

    Table 79. Bedford Pharma Company Detail

    Table 80. Bedford Pharma Business Overview

    Table 81. Bedford Pharma Cancer Generics Product

    Table 82. Bedford Pharma Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 83. Bedford Pharma Recent Development

    Table 84. Hikma Company Detail

    Table 85. Hikma Business Overview

    Table 86. Hikma Cancer Generics Product

    Table 87. Hikma Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 88. Hikma Recent Development

    Table 89. Cipla Company Detail

    Table 90. Cipla Business Overview

    Table 91. Cipla Cancer Generics Product

    Table 92. Cipla Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 93. Cipla Recent Development

    Table 94. Shilpa Medicare Company Detail

    Table 95. Shilpa Medicare Business Overview

    Table 96. Shilpa Medicare Cancer Generics Product

    Table 97. Shilpa Medicare Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 98. Shilpa Medicare Recent Development

    Table 99. Fresenius Kabi Company Detail

    Table 100. Fresenius Kabi Business Overview

    Table 101. Fresenius Kabi Cancer Generics Product

    Table 102. Fresenius Kabi Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 103. Fresenius Kabi Recent Development

    Table 104. Zydus Pharmaceuticals Company Detail

    Table 105. Zydus Pharmaceuticals Business Overview

    Table 106. Zydus Pharmaceuticals Cancer Generics Product

    Table 107. Zydus Pharmaceuticals Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 108. Zydus Pharmaceuticals Recent Development

    Table 109. Neopharm Company Detail

    Table 110. Neopharm Business Overview

    Table 111. Neopharm Cancer Generics Product

    Table 112. Neopharm Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 113. Neopharm Recent Development

    Table 114. Netco Company Detail

    Table 115. Netco Business Overview

    Table 116. Netco Cancer Generics Product

    Table 117. Netco Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 118. Netco Recent Development

    Table 119. Mayne Pharma Company Detail

    Table 120. Mayne Pharma Business Overview

    Table 121. Mayne Pharma Cancer Generics Product

    Table 122. Mayne Pharma Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 123. Mayne Pharma Recent Development

    Table 124. Alvogen Company Detail

    Table 125. Alvogen Business Overview

    Table 126. Alvogen Cancer Generics Product

    Table 127. Alvogen Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 128. Alvogen Recent Development

    Table 129. Glenmark Company Detail

    Table 130. Glenmark Business Overview

    Table 131. Glenmark Cancer Generics Product

    Table 132. Glenmark Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 133. Glenmark Recent Development

    Table 134. HBT Labs Company Detail

    Table 135. HBT Labs Business Overview

    Table 136. HBT Labs Cancer Generics Product

    Table 137. HBT Labs Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 138. HBT Labs Recent Development

    Table 139. Gland Company Detail

    Table 140. Gland Business Overview

    Table 141. Gland Cancer Generics Product

    Table 142. Gland Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 143. Gland Recent Development

    Table 144. Qilu Pharmaceuticals Company Detail

    Table 145. Qilu Pharmaceuticals Business Overview

    Table 146. Qilu Pharmaceuticals Cancer Generics Product

    Table 147. Qilu Pharmaceuticals Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 148. Qilu Pharmaceuticals Recent Development

    Table 149. Akorn Pharmaceuticals Company Detail

    Table 150. Akorn Pharmaceuticals Business Overview

    Table 151. Akorn Pharmaceuticals Cancer Generics Product

    Table 152. Akorn Pharmaceuticals Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 153. Akorn Pharmaceuticals Recent Development

    Table 154. MSN Group Company Detail

    Table 155. MSN Group Business Overview

    Table 156. MSN Group Cancer Generics Product

    Table 157. MSN Group Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 158. MSN Group Recent Development

    Table 159. Wockhardt Company Detail

    Table 160. Wockhardt Business Overview

    Table 161. Wockhardt Cancer Generics Product

    Table 162. Wockhardt Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 163. Wockhardt Recent Development

    Table 164. Rising Pharma Company Detail

    Table 165. Rising Pharma Business Overview

    Table 166. Rising Pharma Cancer Generics Product

    Table 167. Rising Pharma Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 168. Rising Pharma Recent Development

    Table 169. Apotex Company Detail

    Table 170. Apotex Business Overview

    Table 171. Apotex Cancer Generics Product

    Table 172. Apotex Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 173. Apotex Recent Development

    Table 174. Taro Pharmaceuticals Company Detail

    Table 175. Taro Pharmaceuticals Business Overview

    Table 176. Taro Pharmaceuticals Cancer Generics Product

    Table 177. Taro Pharmaceuticals Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 178. Taro Pharmaceuticals Recent Development

    Table 179. Sun Pharma Company Detail

    Table 180. Sun Pharma Business Overview

    Table 181. Sun Pharma Cancer Generics Product

    Table 182. Sun Pharma Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 183. Sun Pharma Recent Development

    Table 184. Alkem Laboratories Company Detail

    Table 185. Alkem Laboratories Business Overview

    Table 186. Alkem Laboratories Cancer Generics Product

    Table 187. Alkem Laboratories Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 188. Alkem Laboratories Recent Development

    Table 189. Endo Pharma Company Detail

    Table 190. Endo Pharma Business Overview

    Table 191. Endo Pharma Cancer Generics Product

    Table 192. Endo Pharma Revenue in Cancer Generics Business (2018-2023) & (US$ Million)

    Table 193. Endo Pharma Recent Development

    Table 194. Research Programs/Design for This Report

    Table 195. Key Data Information from Secondary Sources

    Table 196. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Cancer Generics Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Cancer Generics Market Share by Type: 2022 VS 2029

    Figure 3. Chemotherapy Features

    Figure 4. Biological Targeted Therapy Drugs Features

    Figure 5. Prescription Drugs Features

    Figure 6. Chinese Patent Medicine Features

    Figure 7. Other Features

    Figure 8. Global Cancer Generics Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 9. Global Cancer Generics Market Share by Application: 2022 VS 2029

    Figure 10. Hospital Case Studies

    Figure 11. Clinic Case Studies

    Figure 12. Drug Center Case Studies

    Figure 13. Other Case Studies

    Figure 14. Cancer Generics Report Years Considered

    Figure 15. Global Cancer Generics Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 16. Global Cancer Generics Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 17. Global Cancer Generics Market Share by Region: 2022 VS 2029

    Figure 18. Global Cancer Generics Market Share by Players in 2022

    Figure 19. Global Top Cancer Generics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Generics as of 2022)

    Figure 20. The Top 10 and 5 Players Market Share by Cancer Generics Revenue in 2022

    Figure 21. North America Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. North America Cancer Generics Market Share by Country (2018-2029)

    Figure 23. United States Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Canada Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Europe Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Europe Cancer Generics Market Share by Country (2018-2029)

    Figure 27. Germany Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. France Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. U.K. Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Italy Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Russia Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Nordic Countries Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Asia-Pacific Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Asia-Pacific Cancer Generics Market Share by Region (2018-2029)

    Figure 35. China Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Japan Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. South Korea Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Southeast Asia Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. India Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Australia Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Latin America Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Latin America Cancer Generics Market Share by Country (2018-2029)

    Figure 43. Mexico Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Brazil Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Middle East & Africa Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Middle East & Africa Cancer Generics Market Share by Country (2018-2029)

    Figure 47. Turkey Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 48. Saudi Arabia Cancer Generics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 49. Teva Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 50. Pfizer Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 51. Accord Healthcare Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 52. Amneal Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 53. Mylan Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 54. DrReddy Laboratories Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 55. Bedford Pharma Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 56. Hikma Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 57. Cipla Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 58. Shilpa Medicare Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 59. Fresenius Kabi Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 60. Zydus Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 61. Neopharm Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 62. Netco Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 63. Mayne Pharma Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 64. Alvogen Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 65. Glenmark Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 66. HBT Labs Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 67. Gland Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 68. Qilu Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 69. Akorn Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 70. MSN Group Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 71. Wockhardt Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 72. Rising Pharma Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 73. Apotex Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 74. Taro Pharmaceuticals Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 75. Sun Pharma Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 76. Alkem Laboratories Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 77. Endo Pharma Revenue Growth Rate in Cancer Generics Business (2018-2023)

    Figure 78. Bottom-up and Top-down Approaches for This Report

    Figure 79. Data Triangulation

    Figure 80. Key Executives Interviewed